Aptevo Therapeutics Reports First Quarter 2021 Financial Results
Aptevo Therapeutics Reports First Quarter 2021 Financial Results Advances Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Dosing in Cohort 10 Ongoing SEATTLE, WA / ACCESSWIRE / May 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies, today reported its financial results for the quarter ended March 31, 2021. "We are pleased to report progress...
Source: finanznachrichten.de